Mode
Text Size
Log in / Sign up
Phase 4 Completed N=140 Randomized Triple-blind Treatment

Effect of Dexmedetomidine on Emergence Agitation in Children With or Without Tube Insertion Under General Anesthesia

Myringotomy
Source: ClinicalTrials.gov NCT01535287 ↗
Enrolled (actual)
140
Serious AEs
0.0%
Results posted
Jul 2018
Primary outcomePrimary: Participant's Severity of Emergent Agitation (EA) Using the Pediatric Anesthesia Emergence Delirium (PAED) Scale in PACU (Post-Op Area). — 7; 8 units on a scale
◆ Published Evidence
No publication linked

No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.

Summary

The investigators are inviting your child to participate in this research study because your child is having myringotomy (putting a tiny incision in the eardrum with or without tube insertion) under general anesthesia. The purpose of this study is to determine whether a single injection of Dexmedetomidine (study medication) decreases the frequency of awaking from anesthesia frightened or agitated in children having myringotomy surgery as compared to those children who receive placebo (sterile saltwater).

Outcome Measures

OutcomeResultp-value
PRIMARY
Participant's Severity of Emergent Agitation (EA) Using the Pediatric Anesthesia Emergence Delirium (PAED) Scale in PACU (Post-Op Area).
7; 8
SECONDARY
Duration of Stay in PACU
21; 17
SECONDARY
Respiratory Complications Peri-Operative
0; 0
SECONDARY
Hemodynamic Instability
0; 0
SECONDARY
Post-Operative Behavioral Disturbances
9; 10
SECONDARY
Muscle Pain
0; 0

Eligibility Criteria

Inclusion Criteria

  • ASA I or II (American Society of Anesthesiology classification ASA I means patients without systemic disease, ASA II means patients with one controlled systemic medical disease eg: Diabetes, Hypertension.)
  • Between the ages of 1 and 10 years
  • Undergoing BMT under general anesthesia.

Exclusion Criteria

  • ASA III or higher (Patients with 2 or more medical systemic disease that is not under control, eg: uncontrolled Diabetes)
  • Congenital diseases
  • Coagulation disorders
  • Known allergic reaction to dexmedetomidine
  • Serious preexisting impairment of respiratory, cardiovascular, hepatic, renal, neurological or endocrine functions
  • Severe upper airway infection
  • Predicted difficult airway
  • Preexisting psychiatric disorders
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01535287). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search